Pfizer is due to release its earnings in the US tonight and the stage is set for what's been dubbed "record-shattering revenues", and analysts believe two new products will bring sales beyond the US$1 billion mark. But can the pharmaceutical giant sustain these gains in the medium to long term? Michelle Martin finds out.

Money and Me: What you need to know about CPF’s 2028 new investment scheme today!
18:31

Market View: Oil War Shockwaves - Why Insurance, Defense and AI Are Suddenly Market Movers
20:57

Money and Me: Expensive Mistakes When Market Shocks Hit
25:57